FTSE MIB
33.308,77 -366,38 (-1,09%) Dow Jones
39.150,33 +15,57 (+0,04%) Nasdaq
17.689,36 -32,23 (-0,18%) Nikkei 225
38.596,47 -36,55 (-0,09%) Petrolio
80,59 -0,70 (-0,86%) Bitcoin EUR
60.199,05 +122,61 (+0,20%)
OMGA Jun 2024 2.500 put
| Chiusura precedente | 0,0500 |
| Aperto | 0,2500 |
| Denaro | 0,1000 |
| Domanda | 0,9500 |
| Prezzo d'esercizio | 2,50 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 0,2500 - 0,2500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 508 |
GlobeNewswireOmega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC
Combination of a MYC-targeting epigenomic controller with immune checkpoint or EGFR inhibitor enhanced anti-tumor activity in models of NSCLCCAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced new preclinical data supporting the potential of OTX-2101, a c-MYC-targeting epigenomic controller (MYC-EC) being de
- GlobeNewswire
Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD’s The Liver Meeting® 2023
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical data demonstrating the potential of epigenomic controllers for the treatment of inflammatory and fibrotic liver diseases at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023, takin
- GlobeNewswire
Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical data supporting the potential of OTX-2101, a c-MYC (MYC)-targeting epigenomic controller being developed for the treatment of non-small cell lung cancer (NSCLC), at the upcoming AACR-NCI-EORTC International Conference on
